SCHEMBL15529367

SCHEMBL15529367

CC(C)(C)C(=O)N1CCC(Cc2ccc(NC(=O)N3CC(c4cccnn4)C3)cc2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 4/20 0.49
SMN1; SMN2 Q16637 3/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
MAPT P10636 2/20 0.46
NPC1 O15118 1/20 0.46
STAT1 P42224 1/20 0.46
RAB9A P51151 1/20 0.46
TRPV1 Q8NER1 1/20 0.42
POLB P06746 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
NAMPT P43490 2/20 0.41
GRIN2D O15399 1/20 0.40
GRIN3B O60391 1/20 0.40
GRIN1 Q05586 1/20 0.40
GRIN2A Q12879 1/20 0.40
GRIN2B Q13224 1/20 0.40
GRIN2C Q14957 1/20 0.40
GRIN3A Q8TCU5 1/20 0.40
EPHX2 P34913 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15529360 0.91 FAAH (0.53) FAAHSMN1; SMN2MEN1KMT2AMAPT
SCHEMBL15529071 0.89 FAAH (0.48) FAAHSMN1; SMN2MEN1KMT2AMAPT
SCHEMBL15529309 0.89 NAMPT (0.49) FAAHSMN1; SMN2MEN1KMT2AMAPT
SCHEMBL15529459 0.87 FAAH (0.49) FAAHSMN1; SMN2MEN1KMT2AMAPT
SCHEMBL15529486 0.87 NAMPT (0.54) SMN1; SMN2MAPTNPC1STAT1RAB9A
SCHEMBL15529371 0.86 FAAH (0.48) FAAHSMN1; SMN2MEN1KMT2AMAPT
SCHEMBL15529226 0.86 FAAH (0.48) FAAHSMN1; SMN2MEN1KMT2AMAPT
SCHEMBL15529296 0.85 FAAH (0.53) FAAHSMN1; SMN2MEN1KMT2AMAPT
SCHEMBL15529563 0.85 FAAH (0.47) FAAHSMN1; SMN2MEN1KMT2AMAPT
SCHEMBL15528911 0.84 FAAH (0.45) FAAHSMN1; SMN2MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9296723-B2 NAMPT inhibitors ABBVIE INC. (US) 2016-03-29 US claimed
EP-2852585-A1 NAMPT INHIBITORS AbbVie Inc. (US) 2015-04-01 EP claimed
US-20140336168-A1 NAMPT INHIBITORS ABBVIE INC. 2014-11-13 US claimed
WO-2013170113-A1 NAMPT INHIBITORS ABBVIE INC. (US) 2013-11-14 WO claimed
US-9758511-B2 NAMPT inhibitors ABBVIE INC. (US) 2017-09-12 US disclosed
US-20160168134-A1 NAMPT INHIBITORS ABBVIE INC. (US) 2016-06-16 US disclosed
US-9296723-B2 NAMPT inhibitors ABBVIE INC. (US) 2016-03-29 US disclosed
EP-2852585-A1 NAMPT INHIBITORS AbbVie Inc. (US) 2015-04-01 EP disclosed
US-20140336168-A1 NAMPT INHIBITORS ABBVIE INC. 2014-11-13 US disclosed
WO-2013170113-A1 NAMPT INHIBITORS ABBVIE INC. (US) 2013-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160168134-A1 NAMPT INHIBITORS NAMPT, NNMT, NAPRT FAAH 3211/4885SMN1; SMN2 334/4885MEN1 2691/4885
US-20140336168-A1 NAMPT INHIBITORS NAMPT, NNMT, NAPRT FAAH 3211/4885SMN1; SMN2 334/4885MEN1 2691/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.